Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 1 |
2024 | 2 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease.
Pharmacol Rev. 2022 Jan;74(1):207-237. doi: 10.1124/pharmrev.120.000133.
Pharmacol Rev. 2022.
PMID: 35017177
Free PMC article.
Review.
Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera.
Tong Y, Zhang P, Yang X, Liu X, Zhang J, Grudniewska M, Jung I, Abegg D, Liu J, Childs-Disney JL, Gibaut QMR, Haniff HS, Adibekian A, Mouradian MM, Disney MD.
Tong Y, et al.
Proc Natl Acad Sci U S A. 2024 Jan 9;121(2):e2306682120. doi: 10.1073/pnas.2306682120. Epub 2024 Jan 5.
Proc Natl Acad Sci U S A. 2024.
PMID: 38181056
Item in Clipboard
Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases.
Liu J, Mouradian MM.
Liu J, et al.
Int J Mol Sci. 2024 Feb 17;25(4):2364. doi: 10.3390/ijms25042364.
Int J Mol Sci. 2024.
PMID: 38397040
Free PMC article.
Review.
Item in Clipboard
Targeting transglutaminase 2 as a potential disease modifying therapeutic strategy for synucleinopathies.
Zhang J, Jasutkar HG, Mouradian MM.
Zhang J, et al.
Neural Regen Res. 2021 Aug;16(8):1560-1561. doi: 10.4103/1673-5374.303027.
Neural Regen Res. 2021.
PMID: 33433482
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite